Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. 2016

Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
Department of Gynecology and Obstetrics, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany.

More recently, immunotherapy has emerged as a novel potentially effective therapeutic option also for solid malignancies such as breast cancer (BC). Relevant approaches, however, are determined by the 2 main elements of cancer immunoediting - the elimination of nascent transformed cells by immunosurveillance on the one hand and tumor immune escape on the other hand. Correspondingly, we here review the role of the various cellular immune players within the host-protective system and dissect the mechanisms of immune evasion leading to tumor progression. If the immune balance of disseminated BC cell dormancy (equilibrium phase) is lost, distant metastatic relapse may occur. The relevant cellular antitumor responses and translational immunotherapeutic options will also be discussed in terms of clinical benefit and future directions in BC management.

UI MeSH Term Description Entries

Related Publications

Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
August 2021, Journal of clinical and translational research,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
November 2018, Genome medicine,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
January 2022, Journal of oncology,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
February 2015, Clinical cancer research : an official journal of the American Association for Cancer Research,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
February 2001, Current opinion in molecular therapeutics,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
January 2014, Expert review of clinical immunology,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
January 2018, BioMed research international,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
September 2000, Science (New York, N.Y.),
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
September 2020, International immunopharmacology,
Christoph Domschke, and Andreas Schneeweiss, and Stefan Stefanovic, and Markus Wallwiener, and Joerg Heil, and Joachim Rom, and Christof Sohn, and Philipp Beckhove, and Florian Schuetz
January 2024, Frontiers in immunology,
Copied contents to your clipboard!